What is the pathology of pulmonary arterial hypertension (type 1 pulmonary hypertension)?

Pathology of Pulmonary Arterial Hypertension (Type 1)

Pulmonary arterial hypertension is a panvasculopathy predominantly affecting small pulmonary resistance arteries, characterized by intimal hyperplasia, medial hypertrophy, adventitial proliferation, thrombosis in situ, inflammation, and plexiform arteriopathy—all contributing to progressive vascular obstruction and right ventricular failure 1.

Histopathologic Features

The vascular remodeling in PAH involves multiple layers of the vessel wall simultaneously:

• Intimal hyperplasia: Proliferation of endothelial and smooth muscle cells causing luminal narrowing
• Medial hypertrophy: Thickening of the smooth muscle layer (considered an earlier, more reversible lesion)
• Adventitial proliferation: Thickened, disordered adventitia with excessive metalloprotease activation
• Plexiform arteriopathy: Complex, glomeruloid-like vascular lesions representing advanced disease
• Thrombosis in situ: Intravascular thrombosis contributing to obstruction
• Inflammation: Varying degrees of perivascular inflammatory infiltrates 1

Important caveat: Individual patients may manifest all these lesions with diffuse or focal distribution. Medial hypertrophy represents earlier disease and is more reversible than intimal fibrosis or plexogenic arteriopathy 1.

Molecular and Cellular Pathobiology

The PAH phenotype reflects a "multi-hit model" rather than a single cause 1:

Cellular Abnormalities

• Decreased apoptosis/proliferation ratio in pulmonary artery smooth muscle cells (PASMCs), creating a cancer-like proliferative state
• Endothelial dysfunction with impaired vasodilator production and enhanced vasoconstrictor/mitogenic compound production
• Excessive cell proliferation with resistance to apoptosis 1

Endothelial and Blood Abnormalities

The PAH endothelium produces:

• Increased vasoconstrictors: Endothelin-1 and thromboxane A2
• Decreased vasodilators: Prostacyclin (PGI2)
• Procoagulant state: Elevated fibrinopeptide A and plasminogen activator inhibitor-1, reduced tissue plasminogen activator
• Platelet abnormalities: Serotonin-depleted platelets with elevated plasma serotonin 1

Genetic Basis

Less than 10% of PAH cases are inherited, primarily involving mutations in the transforming growth factor-beta receptor pathway 1:

• BMPR2 mutations: Present in 75% of familial PAH cases, causing loss of function in SMAD signaling pathway
• Activin-like kinase 1 (ALK1) mutations: Found in hereditary hemorrhagic telangiectasia with PAH
• Both mutations result in growth-promoting alterations favoring proliferation over apoptosis 1

Right Ventricular Pathology

Right ventricular function is the major determinant of functional capacity and prognosis in PAH 1. The RV undergoes:

• Hypertrophy and dilatation in response to increased afterload (elevated pulmonary vascular resistance)
• Variable compensatory responses in maintaining stroke volume
• Progressive dysfunction leading to right heart failure as the ultimate cause of death 1

Pathophysiologic Mechanism

PAH results from restricted pulmonary arterial flow causing pathological increases in pulmonary vascular resistance, predominantly due to:

1. Loss of vascular luminal cross-section (primary mechanism) from excessive cell proliferation and reduced apoptosis
2. Excessive vasoconstriction (significant role in approximately 20% of patients) 1

This creates a progressive obstructive vasculopathy rather than simply a vasospastic disorder 2.